Baltimore, Md. and Boston, Mass., June 23, 2014 – The Center for Medical Technology Policy’s (CMTP) Green Park Collaborative (GPC) and the Institute for Clinical and Economic Review (ICER) will co-host a web conference to explore the evidence needed to demonstrate effectiveness and value of new drugs to treat chronic hepatitis C infection. The web conference will take place Monday, July 7, at 12:00 pm EST.
Recently approved medications for hepatitis C have been the focus of attention not only because of their potential effectiveness, but also because of their price tag. Less attention has focused on the amount and quality of clinical and economic evidence currently available, and what can be learned from the first wave of these new drugs regarding the amount and type of evidence needed to inform clinical and policy decision making.
This 90-minute web conference will encourage discussion among stakeholders about the clinical and economic evidence generated for regulatory approval, what additional evidence, if any, would be informative for post-approval decision makers (payers, patients, guideline developers, and policymakers), and strategies to efficiently generate the additional evidence. The discussion will also address evidence generation for hepatitis C drugs that are expected to receive FDA approval later this year.
• Gregg Alton, Executive Vice President, Corporate and Medical Affairs, Gilead Sciences
• Ivonne Perlaza Fuller, Chief Executive Officer, Hepatitis Foundation International
• Michele Manos, Public Health Consultant
• Steve Pearson, President, ICER
• David Ross, Director, HIV, Hepatitis, and Public Health Pathogens Programs (invited)
• To Be Announced Health Plan Representative
The Institute for Clinical and Economic Review (ICER) is an independent non-profit health care research organization dedicated to improving the interpretation and application of evidence in the health care system. ICER directs two core programs: the California Technology Assessment Forum (CTAF), and the New England Comparative Effectiveness Public Advisory Council (CEPAC). For more information about ICER, please visit ICER’s website, www.icer-review.org.
About CMTP and GPC
The Center for Medical Technology Policy (CMTP) has extensive experience convening stakeholder groups to discuss value, and evidence and methodological standards. CMTP’s work on such standards is conducted under the umbrella of the Green Park Collaborative-USA (GPC-USA), a neutral forum to support dialogue and consensus among stakeholders on methodological standards for clinical research, focusing on “real-world” effectiveness and value, and emphasizing evidence expectations of payers, informed by the views of patients and clinicians.